Intellect Dev Disabil. 2014 Feb;52(1):60-77. doi: 10.1352/1934-9556-52.1.60.
Polypharmacy is the concurrent use of multiple medications, including both psychotropic and non-psychotropic drugs. Although it may sometimes be clinically indicated, polypharmacy can have a number of negative consequences, including medication nonadherence, adverse drug reactions, and undesirable drug-drug interactions. The objective of this paper was to gain a better understanding of how to study polypharmacy among people with intellectual and developmental disabilities (IDD). To do this, we reviewed literature on polypharmacy among the elderly and people with IDD to inform future research approaches and methods on polypharmacy in people with IDD. Results identified significant variability in methods used to study polypharmacy, including definitions of polypharmacy, samples studied, analytic strategies, and variables included in the analyses. Four valuable methodological lessons to strengthen future polypharmacy research in individuals with IDD emerged. These included the use of consistent definitions of polypharmacy, the implementation of population-based sampling strategies, the development of clinical guidelines, and the importance of studying associated variables.
同时使用多种药物，包括精神药物和非精神药物，称为多种药物疗法。虽然有时在临床上可能需要使用多种药物疗法，但它可能会产生许多负面影响，包括药物不依从、药物不良反应和不良的药物相互作用。本文的目的是更好地了解如何研究智力和发育障碍（ID）人群中的多种药物疗法。为此，我们回顾了有关老年人和 ID 人群中多种药物疗法的文献，为未来 ID 人群中多种药物疗法的研究方法提供信息。研究结果确定了用于研究多种药物疗法的方法存在显著差异，包括多种药物疗法的定义、研究样本、分析策略以及纳入分析的变量。有四项有价值的方法学经验教训可以加强未来 ID 个体的多种药物疗法研究。这些经验教训包括使用一致的多种药物疗法定义、实施基于人群的抽样策略、制定临床指南以及研究相关变量的重要性。
